Clinuvel Pharmaceuticals Ltd
SWB:UR9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Clinuvel Pharmaceuticals Ltd
SWB:UR9
|
AU |
|
S
|
Supreme PLC
LSE:SUP
|
UK |
|
Capital & Counties Properties PLC
LSE:CAPC
|
UK |
|
Dwarikesh Sugar Industries Ltd
BSE:532610
|
IN |
|
Z
|
Zumtobel Group AG
XMUN:T9Z
|
AT |
|
A
|
Associated British Foods PLC
F:AFO1
|
UK |
|
F
|
Flight Centre Travel Group Ltd
SWB:FLI
|
AU |
|
Kokuyo Co Ltd
F:KOK
|
JP |
Wall St Price Targets
UR9 Price Targets Summary
Clinuvel Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for UR9 is 14.635 EUR with a low forecast of 7.772 EUR and a high forecast of 25.17 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is UR9's stock price target?
Price Target
14.635
EUR
According to Wall Street analysts, the average 1-year price target for UR9 is 14.635 EUR with a low forecast of 7.772 EUR and a high forecast of 25.17 EUR.
What is the Revenue forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Revenue has been 39%. The projected CAGR for the next 8 years is 7%.
What is the Operating Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
9%
The compound annual growth rate for Operating Income over the next 8 years is 9%.
What is the Net Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
10%
The compound annual growth rate for Net Income over the next 8 years is 10%.
